Optimal time-points for detecting expression levels of BAALC, EVI1, and WT1 genes in patients with acute myeloid leukemia: a meta-analysis

References

• Gupta M, Mahapatra M, Saxena R. Cytogenetics’ impact on the prognosis of acute myeloid leukemia. J Lab Physicians. 2019;11(2):133–137.
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Kaspers GJL. How I treat pediatric acute myeloid leukemia. Blood. 2021;138(12):1009–1018.
   PubMed Web of Science ®Google Scholar
• Lussana F, Caprioli C, Stefanoni P, et al. Molecular detection of minimal residual disease before allogeneic stem cell transplantation predicts a high incidence of early relapse in adult patients with NPM1 positive acute myeloid leukemia. Cancers (Basel). 2019;11(10):1455.
   Web of Science ®Google Scholar
• Picharski GL, Andrade DP, Fabro ALMR, et al. The impact of Flt3 gene mutations in acute promyelocytic leukemia: a meta-analysis. Cancers (Basel). 2019;11(9):1311.
   Web of Science ®Google Scholar
• Brand J, van Vliet MH, de Best L, et al. A standardized microarray assay for the independent gene expression markers in AML: EVI1 and BAALC. Exp Hematol Oncol. 2013;2(1):7.
   PubMedGoogle Scholar
• Cilloni D, Gottardi E, De Micheli D. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients Leukemia. Int J Lab Hematol. 2002;16(10):2115–2121.
   Google Scholar
• Eid MA, Attia M, Abdou S, et al. BAALC and ERG expression in acute myeloid leukemia with normal karyotype: impact on prognosis. Int J Lab Hematol. 2010;32(2):197–205.
   PubMed Web of Science ®Google Scholar
• Balgobind BV, Lugthart S, Hollink IH, et al. EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia. Leukemia. 2010;24(5):942–949.
   PubMed Web of Science ®Google Scholar
• Glass C, Wilson M, Gonzalez R, et al. The role of EVI1 in myeloid malignancies. Blood Cells Mol Dis. 2014;53(1-2):67–76.
   PubMed Web of Science ®Google Scholar
• Marjanovic I, Karan-Djurasevic T, Ugrin M, et al. Use of Wilms Tumor 1 gene expression as a reliable marker for prognosis and minimal residual disease monitoring in acute myeloid leukemia with normal karyotype patients. Clin Lymphoma Myeloma Leuk. 2017;17(5):312–319.
   PubMed Web of Science ®Google Scholar
• Marjanovic I, Karan-Djurasevic T, Kostic T, et al. Expression pattern and prognostic significance of EVI1 gene in adult acute myeloid leukemia patients with normal karyotype. Indian J Hematol Blood Transfus. 2020;36(2):292–299.
   PubMed Web of Science ®Google Scholar
• Rashed RA, Kadry DY, El Taweel M, et al. Relation of BAALC and ERG gene expression with overall survival in acute myeloid leukemia cases. Asian Pac J Cancer Prev. 2015;16(17):7875–7882.
   PubMedGoogle Scholar
• Gaiger A, Schmid D, Heinze G, et al. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia. Leukemia. 1998;12(12):1886–1894.
   PubMed Web of Science ®Google Scholar
• Steinleitner K, Rampetsreiter P, Köffel R, et al. EVI1 and MDS1/EVI1 expression during primary human hematopoietic progenitor cell differentiation into various myeloid lineages. Anticancer Res. 2012;32(11):4883–4889.
   PubMed Web of Science ®Google Scholar
• Svedberg H, Richter J, Gullberg U, et al. Forced expression of the Wilms tumor 1 (WT1) gene inhibits proliferation of human hematopoietic CD34 + progenitor cells. Leukemia. 2001;15(12):1914–1922.
   PubMed Web of Science ®Google Scholar
• Langer C, Ruppert AS, Radmacher MD, et al. High BAALC expression associates with other molecular prognostic markers, poor outcome and a distinct gene expression signature in cytogenetically normal acute myeloid leukemia (CN AML): a Cancer and Leukemia Group B (CALGB) study. J Clin Oncol. 2007;25(18):7013.
   Web of Science ®Google Scholar
• Thol F, Yun H, Sonntag AK, et al. Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes. Ann Hematol. 2012;91(8):1221–1231.
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007:8–16.
   PubMed Web of Science ®Google Scholar
• Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–2012.
   PubMed Web of Science ®Google Scholar
• Gianfaldoni G, Mannelli F, Ponziani V, et al. Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia. Haematologica. 2010;95(5):833–836.
   PubMed Web of Science ®Google Scholar
• Yoon JH, Kim HJ, Shin SH, et al. Serial measurement of WT1 expression and decrement ratio until hematopoietic cell transplantation as a marker of residual disease in patients with cytogenetically normal acute myelogenous leukemia. Biology of blood and marrow transplantation. Leukemia. 2013;19(6):958–966.
   Google Scholar
• Nomdedéu JF, Hoyos M, Carricondo M, et al. Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML. Leukemia. 2013;27(11):2157–2164.
   PubMed Web of Science ®Google Scholar
• Rossi G, Minervini MM, Melillo L, et al. Predictive role of minimal residual disease and log clearance in acute myeloid leukemia: a comparison between multiparameter flow cytometry and Wilm's tumor 1 levels. Ann Hematol. 2014;93(7):1149–1157.
   PubMed Web of Science ®Google Scholar
• Malagola M, Skert C, Borlenghi E, et al. Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients. Cancer Med. 2016;5(2):265–274.
   PubMed Web of Science ®Google Scholar
• Rockova V, et al. Early detection of WT1 minimal residual disease predicts outcome in acute myeloid leukemia and identify patients with high risk of relapse independently of allogeneic stem cell transplantation. Blood. 2017;130(Suppl. 1):29.
   Google Scholar
• Rockova V, Abbas S, Wouters BJ, et al. Risk stratification of intermediate-risk acute myeloid leukemia: Integrative analysis of a multitude of gene mutation and gene expression markers. Leuk Lymphoma. 2011;118(4):1069–1076.
   Google Scholar
• Miglino M, Colombo N, Pica G, et al. WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. Leuk Lymphoma. 2011;52(10):1961–1969.
   PubMed Web of Science ®Google Scholar
• Bienz M, Ludwig M, Mueller BU, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res. 2005;11(4):1416–1424.
   PubMed Web of Science ®Google Scholar
• Baldus CD, Thiede C, Soucek S, et al. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. J Clin Oncol. 2006;24(5):790–797.
   PubMed Web of Science ®Google Scholar
• Metzeler KH, Dufour A, Benthaus T, et al. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J Clin Oncol. 2009;27(30):5031–5038.
   PubMed Web of Science ®Google Scholar
• Santamaría C, Chillón MC, García-Sanz R, et al. BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML). Ann Hematol. 2010;89(5):453–458.
   PubMed Web of Science ®Google Scholar
• El-Sharnouby JA, Ahmed LMS, Taha AM, et al. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia patients with normal karyotype. Eur J Gen Med. 2010;7(1):17–28.
   Google Scholar
• Thol F, Damm F, Ludeking A, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol. 2011;29(21):2889–2896.
   PubMed Web of Science ®Google Scholar
• Yoon JH, Kim HJ, Shin SH, et al. Implication of higher BAALC expression in combination with other gene mutations in adult cytogenetically normal acute myeloid leukemia. Leuk Lymphoma. 2014;55(1):110–120.
   PubMed Web of Science ®Google Scholar
• Damiani D, Tiribelli M, Franzoni A, et al. BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients. Am J Hematol. 2013;88(10):848–852.
   PubMed Web of Science ®Google Scholar
• Yahya RS, Sofan MA, Abdelmasseih HM, et al. Prognostic implication of BAALC gene expression in adult acute myeloid leukemia. Clin Lab. 2013;59(5-6):621–628.
   PubMed Web of Science ®Google Scholar
• Weber S, Haferlach T, Alpermann T, et al. Feasibility of BAALC gene expression for detection of minimal residual disease and risk stratification in normal karyotype acute myeloid leukaemia. Br J Haematol. 2016;175(5):904–916.
   PubMed Web of Science ®Google Scholar
• Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood. 2003;101(3):837–845.
   PubMed Web of Science ®Google Scholar
• Lugthart S, Van Drunen E, Van Norden Y, et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood. 2008;111(8):4329–4337.
   PubMed Web of Science ®Google Scholar
• Gröschel S, Lugthart S, Schlenk RF, et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol. 2010;28(12):2101–2107.
   PubMed Web of Science ®Google Scholar
• Zhu YM, Wang PP, Huang JY, et al. Gene mutational pattern and expression level in 560 acute myeloid leukemia patients and their clinical relevance. J Transl Med. 2017;15(1):178.
   PubMedGoogle Scholar
• Ommen HB, Nyvold CG, Braendstrup K, et al. Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Br J Haematol. 2008;141(6):782–791.
   PubMed Web of Science ®Google Scholar
• Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol. 2009;27(31):5195–5201.
   PubMed Web of Science ®Google Scholar
• Voso MT, Ottone T, Lavorgna S, et al. MRD in AML: the role of new techniques. Front Oncol. 2019;9:655.
   PubMed Web of Science ®Google Scholar
• de Boer EN, Johansson LF, de Lange K. Detection of fusion genes to determine minimal residual disease in leukemia using next-generation sequencing. Clin Chem. 2020;66(8):1084–1092.
   PubMed Web of Science ®Google Scholar
• Hokland P, Ommen HB. Towards individualized follow-up in adult acute myeloid leukemia in remission. Blood. 2011;117(9):2577–2584.
   PubMed Web of Science ®Google Scholar
• Wu X, Wang H, Deng J, et al. Prognostic significance of the EVI1 gene expression in patients with acute myeloid leukemia: a meta-analysis. Annals of Hematology. 2019;98(11):2485–2496.
   PubMed Web of Science ®Google Scholar
• Xiao SJ, Shen JZ, Huang JL, et al. Prognostic significance of the BAALC gene expression in adult patients with acute myeloid leukemia: a meta-analysis. Mol Clin Oncol. 2015;3(4):880–888.
   PubMed Web of Science ®Google Scholar
• Yi-Ning Y, Xiao-rui W, Chu-xian Z, et al. Prognostic significance of diagnosed WT1 level in acute myeloid leukemia: a meta-analysis. Ann Hematol. 2015;94(6):929–938.
   PubMed Web of Science ®Google Scholar
• Hinai AA, Valk PJ. Review: aberrant EVI1 expression in acute myeloid leukaemia. Br J Haematol. 2016;172(6):870–878.
   PubMed Web of Science ®Google Scholar
• Weber S, Alpermann T, Dicker F, et al. BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia. Blood Cancer J. 2014;4(1):e173.
   Web of Science ®Google Scholar
• Rossi G, Minervini MM, Carella AM, et al. 2020. Wilms’ tumor gene (WT1) expression and minimal residual disease in acute myeloid leukemia. In: van den Heuvel-Eibrink MM, editor. Wilms tumor. Brisbane: Codon Publications Copyright: The Authors; 2016.
   Google Scholar